Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.85 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618613 | 0.92 | CTSS (1.00) | CTSSMAPTCHRM1CHRM2CHRM4 | |
| SCHEMBL2618855 | 0.90 | CTSS (0.91) | CTSSMAPTS1PR2NPC1 | |
| SCHEMBL2732083 | 0.90 | CTSS (0.91) | CTSSMAPTS1PR2NPC1 | |
| SCHEMBL31285784 | 0.88 | CTSS (1.00) | CTSSMAPTS1PR2LMNATP53 | |
| SCHEMBL2618738 | 0.88 | CTSS (1.00) | CTSSMAPTS1PR2LMNATP53 | |
| SCHEMBL2710565 | 0.88 | CTSS (1.00) | CTSSMAPTS1PR2LMNATP53 | |
| SCHEMBL2712451 | 0.86 | CTSS (0.86) | CTSSMAPTS1PR2LMNATP53 | |
| SCHEMBL2618905 | 0.86 | CTSS (0.86) | CTSSMAPTS1PR2LMNATP53 | |
| SCHEMBL2713563 | 0.86 | CTSS (0.86) | CTSSMAPTS1PR2LMNATP53 | |
| SCHEMBL2113182 | 0.84 | CTSS (0.65) | CTSSMAPTCHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | CTSS 1/4885MAPT 940/4885CHRM1 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.